Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × nimotuzumab × 30 days × Clear all

Phase

Phase 3 1 Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 1

Interventions

Magnetic Resonance Spectroscopy 14 Cisplatin 13 Specimen Handling 12 pembrolizumab 8 Nivolumab 8 Carboplatin 8 Platinum 7 Paclitaxel 7 Gemcitabine 7 1,2-diaminocyclohexaneplatinum II citrate 7 atezolizumab 6 Doxorubicin 6 Radiotherapy 5 Radiation 5 Biopsy 5 Bevacizumab 5 Pemetrexed 4 Immunoglobulin G 4 Disulfides 4 Rituximab 3 Radiotherapy, Intensity-Modulated 3 Prednisone 3 Ipilimumab 3 Cyclophosphamide 3 Capecitabine 3 Androgen Antagonists 3 130-nm albumin-bound paclitaxel 3 venetoclax 2 prednylidene 2 merphos 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07535567 2026-04-17

NimoBenSeq

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Phase 2/3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon ⚡